benzoxazoles has been researched along with plx4032 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arnér, ES; Brodin, B; Campbell, J; Drummond, CJ; Higgins, M; Laín, S; McCarthy, AR; Sachweh, MC; Stafford, WC | 1 |
Cheng, Y; Tian, H; Wang, X; Xia, X; Zhang, W | 1 |
2 other study(ies) available for benzoxazoles and plx4032
Article | Year |
---|---|
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.
Topics: Animals; Antineoplastic Agents; Auranofin; Benzothiazoles; Benzoxazoles; Cell Line, Tumor; Cell Survival; Enzyme Activation; Glutathione; Glutathione Reductase; HCT116 Cells; Humans; Imidazoles; Indoles; Melanoma; Mice; Oxidation-Reduction; Oxidative Stress; Piperazines; Reactive Oxygen Species; Sulfonamides; Sulfones; Thioredoxin Reductase 1; Tumor Suppressor Protein p53; Vemurafenib | 2015 |
A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer.
Topics: Animals; Benzoxazoles; Biological Availability; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Female; HT29 Cells; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Vemurafenib; Xenograft Model Antitumor Assays | 2019 |